Skip to main content

All Access Subscription

Get unlimited access to our full publication and article library.

Get Access Now

Interested in Group Sales? Learn more

In a phase-II study for patients with relapsed or refractory carcinoma of unknown primary, the combination of oxaliplatin and capecitabine was found to be both active and reasonably well tolerated.

Xelox for Second-line Treatment of CUP